Share this video  

GU Cancers 2019 | Update on PACE and ARAMIS trials for prostate cancer

Joe O’Sullivan, MD, FRCR, FFRRCSI, FRCPI, of Queen’s University Belfast, Belfast, UK, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA. and discusses the PACE trial (NCT01584258), which found that stereotactic body radiation therapy had reduced acute toxicity compared to the standard treatment of intensity-modulated radiation therapy for organ confined low and intermediate risk prostate cancer. Prof. O’Sullivan goes on to discuss the ARAMIS trial (NCT02200614), which found that darolutamide had a good toxicity profile compared to enzalutamide, and is effective in the treatment of M0 castrate-resistant prostate cancer.